Literature DB >> 34806245

Structural characterization of a pathogenic mutant of human protein tyrosine phosphatase PTPN2 (Cys216Gly) that causes very early onset autoimmune enteropathy.

Qing Nian1,2, Jérémy Berthelet2, Marianna Parlato3, Ariel E Mechaly4, Rongxing Liu2, Jean-Marie Dupret2, Nadine Cerf-Bensussan3, Ahmed Haouz4, Fernando Rodrigues Lima2.   

Abstract

PTPN2 is an important protein tyrosine phosphatase (PTP) that plays a key role in cell signaling. Deletions or inactivating mutations of PTPN2 have been described in different pathologies and underline its critical role in hematopoiesis, autoimmunity, and inflammation. Surprisingly, despite the major pathophysiological implications of PTPN2, the structural analysis of this PTP and notably of its pathogenic mutants remains poorly documented. Contrary to other human PTP enzymes, to date, only one structure of PTPN2 (wild-type form) has been reported. Here, we report the first crystal structure of a pathogenic mutant of PTPN2 (Cys216Gly) that causes an autoimmune enteropathy. We show in particular that this mutant adopts a classical PTP fold. More importantly, albeit inactive, the mutant retains its ability to bind substrates and to adopt the characteristic catalytically competent closed form of PTP enzymes. This novel PTPN2 structure may serve as a new tool to better understand PTP structures and the structural impacts of pathogenic mutations. Moreover, the C216G PTPN2 structure could also be helpful to design specific ligands/inhibitors.
© 2021 The Protein Society.

Entities:  

Keywords:  PTPN2; crystal structure; pathogenic mutation; protein tyrosine phosphatase

Mesh:

Substances:

Year:  2021        PMID: 34806245      PMCID: PMC8820110          DOI: 10.1002/pro.4246

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  23 in total

1.  PTPN2 restrains CD8⁺ T cell responses after antigen cross-presentation for the maintenance of peripheral tolerance in mice.

Authors:  Florian Wiede; Alexandra Ziegler; Dietmar Zehn; Tony Tiganis
Journal:  J Autoimmun       Date:  2014-07-02       Impact factor: 7.094

Review 2.  The dead phosphatases society: a review of the emerging roles of pseudophosphatases.

Authors:  Veronika Reiterer; Krzysztof Pawłowski; Guillaume Desrochers; Arnim Pause; Hayley J Sharpe; Hesso Farhan
Journal:  FEBS J       Date:  2020-06-16       Impact factor: 5.542

3.  Substrate-trapping techniques in the identification of cellular PTP targets.

Authors:  C Blanchetot; M Chagnon; N Dubé; M Hallé; M L Tremblay
Journal:  Methods       Date:  2005-01       Impact factor: 3.608

4.  Structural characterization of a pathogenic mutant of human protein tyrosine phosphatase PTPN2 (Cys216Gly) that causes very early onset autoimmune enteropathy.

Authors:  Qing Nian; Jérémy Berthelet; Marianna Parlato; Ariel E Mechaly; Rongxing Liu; Jean-Marie Dupret; Nadine Cerf-Bensussan; Ahmed Haouz; Fernando Rodrigues Lima
Journal:  Protein Sci       Date:  2021-11-27       Impact factor: 6.725

Review 5.  Protein tyrosine phosphatases: structure, function, and implication in human disease.

Authors:  Lutz Tautz; David A Critton; Stefan Grotegut
Journal:  Methods Mol Biol       Date:  2013

6.  Protein tyrosine phosphatases PTP-1B and TC-PTP play nonredundant roles in macrophage development and IFN-gamma signaling.

Authors:  Krista M Heinonen; Annie Bourdeau; Karen M Doody; Michel L Tremblay
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-27       Impact factor: 11.205

7.  PTPN2 phosphatase deletion in T cells promotes anti-tumour immunity and CAR T-cell efficacy in solid tumours.

Authors:  Florian Wiede; Kun-Hui Lu; Xin Du; Shuwei Liang; Katharina Hochheiser; Garron T Dodd; Pei K Goh; Conor Kearney; Deborah Meyran; Paul A Beavis; Melissa A Henderson; Simone L Park; Jason Waithman; Sheng Zhang; Zhong-Yin Zhang; Jane Oliaro; Thomas Gebhardt; Phillip K Darcy; Tony Tiganis
Journal:  EMBO J       Date:  2019-12-05       Impact factor: 11.598

Review 8.  The Roles of Pseudophosphatases in Disease.

Authors:  Andrew M Mattei; Jonathan D Smailys; Emma Marie Wilber Hepworth; Shantá D Hinton
Journal:  Int J Mol Sci       Date:  2021-06-28       Impact factor: 5.923

9.  Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC.

Authors:  Marcus Grohmann; Florian Wiede; Garron T Dodd; Esteban N Gurzov; Geraldine J Ooi; Tariq Butt; Aliki A Rasmiena; Supreet Kaur; Twishi Gulati; Pei K Goh; Aislinn E Treloar; Stuart Archer; Wendy A Brown; Mathias Muller; Matthew J Watt; Osamu Ohara; Catriona A McLean; Tony Tiganis
Journal:  Cell       Date:  2018-10-25       Impact factor: 41.582

10.  Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy.

Authors:  Jun Wei; Lingyun Long; Wenting Zheng; Yogesh Dhungana; Seon Ah Lim; Cliff Guy; Yanyan Wang; Yong-Dong Wang; Chenxi Qian; Beisi Xu; Anil Kc; Jordy Saravia; Hongling Huang; Jiyang Yu; John G Doench; Terrence L Geiger; Hongbo Chi
Journal:  Nature       Date:  2019-12-11       Impact factor: 49.962

View more
  2 in total

1.  Structural characterization of a pathogenic mutant of human protein tyrosine phosphatase PTPN2 (Cys216Gly) that causes very early onset autoimmune enteropathy.

Authors:  Qing Nian; Jérémy Berthelet; Marianna Parlato; Ariel E Mechaly; Rongxing Liu; Jean-Marie Dupret; Nadine Cerf-Bensussan; Ahmed Haouz; Fernando Rodrigues Lima
Journal:  Protein Sci       Date:  2021-11-27       Impact factor: 6.725

2.  Biochemical, Enzymatic, and Computational Characterization of Recurrent Somatic Mutations of the Human Protein Tyrosine Phosphatase PTP1B in Primary Mediastinal B Cell Lymphoma.

Authors:  Rongxing Liu; Yujie Sun; Jérémy Berthelet; Linh-Chi Bui; Ximing Xu; Mireille Viguier; Jean-Marie Dupret; Frédérique Deshayes; Fernando Rodrigues Lima
Journal:  Int J Mol Sci       Date:  2022-06-24       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.